European Real-world Data About the Use of a New Delivery System Containing a Preservative-free Multi-dose Glaucoma Treatment

Overview

Journal Eur J Ophthalmol

Specialty Ophthalmology

Date 2020 May 8

PMID 32375561

Citations 3

Authors

Philippe Denis

Susana Duch

Enping Chen

Per Klyve

Jesper Skov

Paivi Puska

Carl Erb

Affiliations

Soon will be listed here.

Abstract

Background: Glaucoma treatments are mostly presented in uni-dose or multi-dose format. A certain number of patients with visual acuity and dexterity problems may have problems in instilling eye drops.

Aim: To assess patient satisfaction and ease of use of a preservative-free glaucoma treatment (dorzolamide/timolol) in a new and innovative patented multi-dose delivery system.

Methods: Retrospective, international, multicentre, non-interventional study in 788 adult patients using a multi-dose delivery system for at least 28 days.

Results: Mean patient age was 68.1 ± 12.1 years. Mean duration of multi-dose delivery system use was 132.1 ± 125.1 days; 66.5% of the patients previously used multi-dose and 33.5% uni-dose delivery systems (n = 734); 78.3% of the patients were satisfied or very satisfied with the multi-dose delivery system. A significant majority (all p ≤ 0.045) of patients with a QuickDash® score between [0 to 25[ (66.4%, n = 211) and [50 to 75[ (81.8%, n = 11) rated multi-dose delivery system as easy or very easy to open and significantly more subjects in the [0 to 25[ (72%) score group rated multi-dose delivery system as being better or much better than their previous device (n = 211). Significantly (all p < 0.01) more subjects with available visual acuity results rated multi-dose delivery system as good, better or much better than their previous dispensing device.

Conclusion: The tested multi-dose delivery system was highly accepted. It is, therefore, suitable for glaucoma patients with decreased visual acuity and/or dexterity problems. Further studies may be necessary to assess the easiness of use of this easy-to-grip delivery system.

Citing Articles

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.

Leonardi A, Quintieri L, Presa I, LLoves J, Montero J, Benitez-Del-Castillo J Curr Allergy Asthma Rep. 2024; 24(7):347-360.

PMID: 38869807 PMC: 11233348. DOI: 10.1007/s11882-024-01150-0.

Quality of Life in Digital Device Users Who are Treated with Systane Hydration PF.

Pucker A, Lievens C, McGwin Jr G, Franklin Q, Logan A, Wolfe G Clin Optom (Auckl). 2023; 15:45-54.

PMID: 36915855 PMC: 10007863. DOI: 10.2147/OPTO.S398496.

Limiting plastic waste in dry eye practice for environmental sustainability.

Govindasamy G, Lim C, Riau A, Tong L Ocul Surf. 2022; 25:87-88.

PMID: 35613675 PMC: 9124366. DOI: 10.1016/j.jtos.2022.05.005.

References

Nordmann J, Akesbi J . [Improve adherence in glaucoma patients: a doctor's duty]. J Fr Ophtalmol. 2011; 34(6):403-8. DOI: 10.1016/j.jfo.2011.04.003. View

Chou C, Cotch M, Vitale S, Zhang X, Klein R, Friedman D . Age-related eye diseases and visual impairment among U.S. adults. Am J Prev Med. 2013; 45(1):29-35. PMC: 4072030. DOI: 10.1016/j.amepre.2013.02.018. View

Gao X, Yang Q, Huang W, Chen T, Zuo C, Li X . Evaluating Eye Drop Instillation Technique and Its Determinants in Glaucoma Patients. J Ophthalmol. 2018; 2018:1376020. PMC: 5911316. DOI: 10.1155/2018/1376020. View

. Recommendations for professional standards and good epidemiological practices (version France 2007). Rev Epidemiol Sante Publique. 2008; 56 Spec No 1:S121-75. View

Munoz Negrete F, Lemij H, Erb C . Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin Ophthalmol. 2017; 11:557-566. PMC: 5367594. DOI: 10.2147/OPTH.S126042. View

Dietlein T, Jordan J, Luke C, Schild A, Dinslage S, Krieglstein G . Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol. 2008; 86(8):856-9. DOI: 10.1111/j.1755-3768.2007.01155.x. View

Lemij H, Hoevenaars J, van der Windt C, Baudouin C . Patient satisfaction with glaucoma therapy: reality or myth?. Clin Ophthalmol. 2015; 9:785-93. PMC: 4427261. DOI: 10.2147/OPTH.S78918. View

Atey T, Shibeshi W, Giorgis A, Asgedom S . The Impact of Adherence and Instillation Proficiency of Topical Glaucoma Medications on Intraocular Pressure. J Ophthalmol. 2017; 2017:1683430. PMC: 5618783. DOI: 10.1155/2017/1683430. View

Baudouin C, Renard J, Nordmann J, Denis P, Lachkar Y, Sellem E . Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012; . DOI: 10.5301/ejo.5000181. View

10.

Tham Y, Li X, Wong T, Quigley H, Aung T, Cheng C . Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081-90. DOI: 10.1016/j.ophtha.2014.05.013. View

11.

Gabisson P, Briat B, Le Foll J, Conan S, Bale-Le Bescond F, Talmud M . [Handiness and acceptability of the new Abak bottle in chronically treated patients. A cross-sectional, retrospective and multicentre study]. Ann Pharm Fr. 2011; 69(1):22-9. DOI: 10.1016/j.pharma.2010.10.001. View

12.

Davis S, Sleath B, Carpenter D, Blalock S, Muir K, Budenz D . Drop instillation and glaucoma. Curr Opin Ophthalmol. 2017; 29(2):171-177. PMC: 6422028. DOI: 10.1097/ICU.0000000000000451. View

13.

Stewart W, Stewart J, Nelson L . Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011; 36(5):391-8. DOI: 10.3109/02713683.2011.562340. View

14.

Beaton D, Wright J, Katz J . Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am. 2005; 87(5):1038-46. DOI: 10.2106/JBJS.D.02060. View

15.

Nordmann J, Baudouin C, Bron A, Denis P, Rouland J, Sellem E . Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol. 2009; 19(6):949-56. DOI: 10.1177/112067210901900609. View

16.

Nordmann J, Auzanneau N, Ricard S, Berdeaux G . Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003; 1:75. PMC: 317367. DOI: 10.1186/1477-7525-1-75. View

17.

Goldberg I, Graham S, Crowston J, DMellow G . Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol. 2014; 43(3):214-20. DOI: 10.1111/ceo.12431. View

18.

Barnebey H, Robin A . Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial. Am J Ophthalmol. 2016; 176:61-69. DOI: 10.1016/j.ajo.2016.12.002. View

19.

Leung E, Medeiros F, Weinreb R . Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17(5):350-5. DOI: 10.1097/IJG.0b013e31815c5f4f. View

20.

Aptel F, Labbe A, Baudouin C, Bron A, Lachkar Y, Sellem E . [Glaucoma medications, preservatives and the ocular surface.]. J Fr Ophtalmol. 2014; 37(9):728-736. DOI: 10.1016/j.jfo.2014.06.005. View